What's useful
- Experiment records: protocols, conditions, raw results and analysis, ideally from an electronic lab notebook.
- Assay and screening data linked to the compounds, constructs or samples tested.
- Instrument data: plate reader, sequencing, imaging or chromatography outputs.
- Trial data you own, where consent and approvals allow it (see below).
What qualifies
The listing is for labs and companies of roughly 10 to 1,000 employees that own their research records outright.
What to check first
- Who owns the data. Collaboration agreements, university partnerships, CRO contracts and grant terms often decide who owns results. Check them project by project.
- Human participants. Data from clinical studies or human samples is usually special category data under UK GDPR. Participants' consent and the ethics approval (through a research ethics committee and the Health Research Authority, where it applies) may not cover licensing to a third party. Leave human data out unless your governance lead confirms it's allowed.
- Animal and environmental work. Usually less restricted, but check funder and partner terms.
- Unpublished IP. Keep anything that might be patented out until filings are made.
What it's worth
Mercor lists potential company earnings of $50kâ$875k for biotech and life sciences labs, depending on what's in scope. That is Mercor's own figure, not a promise or guarantee from us.
Are negative results useful?
Very. Experiments that didn't work are rarely published, which makes them scarce.
Our notebooks are partly on paper. Does that rule us out?
No, but digital records are easier to scope. Mention what format your records are in when you get in touch.